ScripCasualties Of Risk-Off My time in the City included the management of four UK-listed biotech investment trusts and unit trusts. Investment trusts date back to the mid-1800s and can invest in both priv
In VivoRising Leaders Home One of In Vivo ’s 2024 Rising Leaders, Tuyen Ong is familiar with scaling biotech companies. He was previously chief development officer at Nightstar Therapeutics plc until it
In VivoOphthalmic gene therapy company Beacon Therapeutics was launched in June 2023 with a £96m ($120m) series A financing. The company was created by VC firm Syncona Investment Management, which combined A
ScripOnly days after announcing a plan to reduce expenses by $1bn, Biogen, Inc. reeled in the third-largest biopharma M&A deal of 2023, agreeing to pay $7.3bn on 28 July for Reata Pharmaceuticals, Inc.